Expression of midkine and endoglin in breast carcinomas with different immunohistochemical profiles

APMIS

Volumn 119, Issue 2, 2011, Pages 103-110

  Qin Li, Li ^a   Lian Huang, Hui ^a   Liang Ping, Jin ^a   Xu, Wei ^a   Li, Jing ^a   Cheng Dai, Li ^a  

^a HUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Basal like subtype; Breast carcinoma; Endoglin; Immunohistochemistry; Midkine

Indexed keywords

ENDOGLIN; MIDKINE;

ARTICLE; BREAST CARCINOMA; CANCER STAGING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; ANTIGENS, CD; BREAST NEOPLASMS; CYTOKINES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, CELL SURFACE;

EID: 78650810374     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2010.02699.x     Document Type: Article

References (22)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23.
4. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
5. Sasaki Y, Tsuda H. Clinicopathological characteristics of triple-negative breast cancers. Breast Cancer 2009;16:254-9.
6. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009;20:1913-27.
7. Greenberg S, Rugo HS. Triple-negative breast cancer: role of antiangiogenic agents. Cancer J 2010;16:33-8.
8. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008;11:79-89.
9. Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A, Hamanoue M, Takao S, et al. A new family of heparinbinding growth/differentiation factors: increased midkine expression in Wilm's tumour and other human carcinomas. Cancer Res 1993;53:1281-5.
10. Garver RI Jr., Radford DM, Donis-Keller H, Wick MR, Milner PG. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 1994;74:1584-90.
11. Aridome K, Tsutsui J, Takao S, Kadomatsu K, Ozawa M, Aikou T, et al. Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res 1995;86:655-61.
12. Garver RI, Chan CS, Milner PG. Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues. Am J Res Cell Mol Biol 1993;9:463-6.
13. Friedrich C, Holtkamp N, Cinatl J Jr., Sakuma S, Mautner VF, Wellman S, et al. Overexpression of midkine in malignant peripheral nerve sheath tumor cells inhibits apoptosis and increases angiogenic potency. Int J Oncol 2005;27:1433-40.
14. Ruan M, Ji T, Wu Z, Zhou J, Zhang C. Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis. Int J Oral Maxillofac Surg 2007;36:159-64.
15. Rodríguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006;12:1533-9.
16. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.
17. Rakha EA, EL-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
18. Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007;9:R4.
19. Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtio J, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009;20:1639-46.
20. Lopes N, Sousa B, Vieira D, Milanezi F, Schmitt F. Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles. Histopathology 2009;55:594-9.
21. Dai LC, Wang X, Yao X, Lu YL, Ping JL, He JF, et al. Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis. World J Gastroenterol 2007;13:1208-13.
22. Dales JP, Garcia S, Bonnier P, Duffaud F, Andrac-Meyer L, Ramuz O, et al. CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am J Clin Pathol 2003;119:374-80.